Stefan D. Anker
Prof. Stefan D. Anker, MD, PhD, FESC (September, 2016)
– born September 19th 1965 in Berlin, Germany
– married, 1 son
– contact: University Medical Center Göttingen, Innovative Clinical Trials,
Robert-Koch-Straße 40, D-37075 Göttingen, Germany
Stefan D. Anker is Professor of Innovative Clinical Trials (W3) at University Medical Center Göttingen (from
September 2014). Dr. Anker studied medicine at Charité Berlin and then started his clinical training in
Germany completing it in the UK. He obtained his M.D. from Charité Medical School, Berlin, Germany
(1993). He went on to earn a Ph.D. (1998) at the National Heart & Lung Institute of Imperial College
London. Dr Anker was Professor of Cardiology & Cachexia Research (W2) at Charité Berlin (2002-14).
Dr. Anker has authored more than 650 original papers, reviews, and editorials that are well cited (total
citations: >40,000, h-index: 101, papers with ≥200 citations: 47; source: Scopus, 1st September, 2016).
For his work Dr. Anker has won several prizes (including 2 AHA-YIAs), and has obtained a number of
fellowships and grants, including 2 NIH grants (WARCEF trial), 2 EU-FP7 grants & 1 IMI/Horizon2020
grant. Dr. Anker was co-ordinator for “SICA-HF” study (EU-FP7).
Dr. Anker is Vice President of the European Society of Cardiology (ESC, 2016-18), serving on the ESC
board since 2012. Dr. Anker serves in the board of the Heart Failure Association (HFA) of the ESC since
2006; he was HFA President (2012-14), and currently chairs the HFA committee on regulatory affairs. Dr.
Anker is founding Editor-in-Chief of the first open access heart failure journal ESC Heart Failure.
Dr. Anker serves on the editorial boards of 5 scientific journals (including European Heart Journal,
European Journal of Heart Failure & IJC), and he worked in several ESC Guideline task forces.
Dr. Anker is the founding president of the International Society on Sarcopenia, Cachexia and Wasting
Disorders (SCWD – see www.cachexia.org). Dr. Anker is founding Editor-in-Chief of the Journal of
Cachexia, Sarcopenia and Muscle (JCSM, 2015-IF 7.88, see www.jcsm.info).
Dr. Anker was and is member of >25 international clinical trial steering committees, chairing or co-chairing
several (incl. FAIR-HF & FAIR-HF2, TIM-HF, AUGMENT-HF, RESHAPE-HF2, IMPULSE-HF and
BACH). He served in a number of DMC’s (chairing 4) and end-point committees (chairing 4).
1. Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor of survival in chronic heart failure.
2. Anker SD, Chua TP, Swan JW, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure:
The importance for cardiac cachexia. Circulation 1997;96:526-34.
3. Niebauer J, Volk H-D, Kemp M, et al & Anker SD.Endotoxin and immune activation in chronic heart failure: a
prospective cohort study. Lancet 1999;353:1838-42.
4. Anker SD, Negassa A, Coats AJS, et al. Prognostic importance of weight loss in chronic heart and the effect of
treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 2003;361:1077-83.
5. Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency.
N Engl J Med 2009;361:2436-48.
6. Maisel A, Mueller C, et al. & Anker SD. Mid-region pro-hormone markers for diagnosis and prognosis in acute
dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2010;55:2062-76.
7. Koehler F, Winkler S, Schieber M, et al. & Anker SD. Impact of Remote Telemedical Management on Mortality and
Hospitalizations in Ambulatory Patients With Chronic Heart Failure: The Telemedical Interventional Monitoring in
Heart Failure Study. Circulation 2011;123:1873-80.
8. Anker SD, Koehler F, Abraham WT. Telemedicine and remote patient management in heart failure. Lancet
9. Homma S, …, Anker SD, …; WARCEF Investigators. Warfarin and aspirin in patients with heart failure and sinus
rhythm. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med. 2012;366:1859-69.
10. Ponikowski P, et al. & Anker SD. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose
in patients with symptomatic heart failure and iron deficiency†. Eur Heart J. 2015;36,657–68.